1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Biocept, Inc.

Biocept, Inc.

BIOCQ
Biocept, Inc.US flagOther OTC
0.00
USD
- -
- -
525.00Market Cap
Biocept, Inc.
BIOCQ
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
TTM
FRC
6.3
654.43
803.86
813.51
837.79
3,029.23
1,659.14
348.48
80.28
69.55
124.36
45.76
-10.98
Revenue per Share
-81,612.49
-73,410.34
-55,288.52
-96,744.18
-23,282.32
-17,292.6
-7,074.87
-2,634.46
-365.01
-45.1
-5.73
-56.78
-53.99
Basic EPS, GAAP
-67,543.39
-51,587.2
-37,144.16
-91,284.01
-21,043.96
-15,205.94
-6,890.64
-2,412.4
-345.36
-52.31
4.3
-24.94
-25.03
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-604,360.78
-677,771.12
-733,059.62
-843,210.84
-213,236.12
-163,189.96
-63,911.45
-23,636.44
-3,567.88
-667.42
-540.78
-528.09
-423.49
Book Value per Share
-92,097.13
-163,997.68
-74,628.48
-1,344.93
5,072.44
619.04
424.23
326.21
162.64
60
76.1
15.68
0.4
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
Basic Weighted Avg Shares
- -
- -
- -
- -
1
3
5
3
6
27
61
26
-8
Sales/Revenue/Turnover
-1,166,444.49
-9,610.37
-5,917.86
-10,399.07
-2,690.7
-559.25
-417.76
-746.35
-417.05
-56.33
-3.93
-123.69
523.6
Operating Margin (%)
- -
- -
- -
- -
- -
- -
1
1
1
1
2
2
2
Depreciation Expense
-14
-12
-9
-16
-17
-18
-22
-25
-25
-18
-3
-32
-39
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-1,295,559.51
-11,217.53
-6,877.86
-11,892.25
-2,779.03
-570.86
-426.42
-755.98
-454.69
-64.84
-4.61
-124.09
491.79
Profit Margin (%)
-15
-27
-12
4
6
1
- -
1
8
20
34
11
4
Working Capital
2
1
- -
5
3
2
1
1
1
11
11
10
10
LT Debt
-15
-27
-12
- -
4
1
1
3
11
24
37
9
- -
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'22
Mar'23
Jun'23
ST Debt
2
2
2
LT Borrowings
- -
- -
- -
LT Finance Leases
10
10
10
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1
1
2
Market Capitalization
3
2
- -

Working Capital

FRC

•

in mil. unless spec.
Dec'22
Mar'23
Jun'23
Total Current Assets
16
9
9
Cash, Cash Equivalents & STI
13
7
7
Accounts Receivable, Net
2
1
1
Inventories
1
1
1
Total Current Liabilities
6
4
5
Payables & Accruals
3
2
3
ST Debt
2
2
2
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-141.61%
99.25%
-76.36%
Free Cash Flow
-72.5%
-175.27%
-765.53%
Net Income, GAAP
101.89%
187.79%
1,036.23%
Sales/Revenue/Turnover
136.13%
99.24%
-57.78%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
18
12
17
14
61
2022
20
6
1
-10
26
2023
1
1
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
5.82
-4.07
-1.22
-7.18
-5.73
2022
-3.93
-17.82
-17.87
- -
-56.78
2023
-12.16
-3.5
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
Similar Companies
Exact Sciences Corporation (EXAS)
Guangdong Hybribio Biotech Co.,Ltd. (300639.SZ)
Genetic Technologies Limited (GTG.AX)
Metropolis Healthcare Limited (METROPOLIS.BO)
Genetics Generation Advancement Corp. (4160.TWO)
Access Bio, Inc. (950130.KQ)
Business
Biocept, Inc. (BIOCQ) operates as a molecular oncology diagnostics company that develops and commercializes proprietary clinical diagnostic laboratory assays, including the CNSide assay, to identify rare tumor cells, cell-free tumor DNA (ctDNA), and circulating tumor RNA (ctRNA) from blood, cerebrospinal fluid (CSF), and other samples; its core offerings encompass Target Selector liquid biopsy tests for solid tumors such as breast, non-small cell lung, gastric, colorectal, prostate, pancreaticobiliary, and ovarian cancers, along with CSF tumor cell enumeration and biomarker analysis services for carcinomas and melanomas, provided through its CLIA-certified laboratory to oncologists, neuro-oncologists, and pharmaceutical firms for patient monitoring, targeted therapy selection, clinical trials, and research. The company, founded in 1997 and headquartered at 9955 Mesa Rim Road in San Diego, California, previously manufactured microfluidic channels, reagents, and equipment for these assays while targeting U.S. healthcare providers and biopharma partners. In October 2023, Biocept filed a voluntary Chapter 7 bankruptcy petition in the U.S. Bankruptcy Court for the District of Delaware, initiating asset liquidation with reported assets of $2.49 million against $2.92 million in liabilities, accompanied by the resignation of its president, CEO, and board members; ongoing trustee actions through 2024 included equipment sales and claim extensions, marking the cessation of operations.